Why T-CURX’s Pantherna acquisition could matter for the future of cell therapy manufacturing
T-CURX and Pantherna are combining CAR-T, mRNA and LNP platforms. Europe’s in vivo cell therapy race just became more serious.
Could Therorna’s circRNA in vivo CAR-T platform change autoimmune disease treatment?
CAR-T is powerful but hard to scale. Therorna’s circRNA platform tests whether in vivo engineering can move the field beyond bespoke therapy.
What Lilly’s Orna Therapeutics deal means for immune reset strategies
Eli Lilly and Company has entered into a definitive agreement to acquire Orna Therapeutics, Inc., gaining access to the biotechnology firm’s circular RNA platform and its clinical trial ready in vivo CAR-T candidate ORN-252 targeting CD19 for B cell driven autoimmune diseases. The deal, valued at up to 2.4 billion dollars in cash including milestone […]
CREATE’s in vivo CAR-T achieves full B cell depletion and repeat dosing in primates
CREATE Medicines shows redosable B cell depletion in primates with in vivo CAR-T platform. Find out what this means for autoimmune and oncology therapy.